[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fEk-ZvyRSjP0NivYEsZEC5mH3ZPKo722xkb9tTh0trAI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":36,"phaseBuckets":37,"rows":44},"Johnson & Johnson Vision Care, Inc.",[4],219,false,1,25698,0,215,[13,16,19,22,25,28,31,34],{"name":14,"count":15},"Visual Acuity",97,{"name":17,"count":18},"Myopia",42,{"name":20,"count":21},"Astigmatism",15,{"name":23,"count":24},"Refractive Error",13,{"name":26,"count":27},"Presbyopia",9,{"name":29,"count":30},"Ocular Physiology",6,{"name":32,"count":33},"Ametropia",4,{"name":35,"count":33},"Visual Performance",[],[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,84,109,127,151,169],{"intervention":46,"totalTrials":47,"cells":48},"Blink® Tears eye drops",2,{"EARLY_PHASE1":49,"PHASE1":51,"PHASE2":64,"PHASE3":78,"PHASE4":80,"NA":82},{"trials":50,"activeCount":10},[],{"trials":52,"activeCount":10},[53],{"nctId":54,"briefTitle":55,"status":56,"phases":57,"primaryCompletion":58,"completion":58,"start":59,"enrollment":60,"conditions":61,"interventions":62},"NCT06131476","Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of a Lipid- Based Lubricating Eye Drop","COMPLETED",[39],"2020-10-10","2020-09-16",32,[14],[46,63],"Investigational lipid eye drops",{"trials":65,"activeCount":10},[66],{"nctId":67,"briefTitle":68,"status":56,"phases":69,"primaryCompletion":70,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":75},"NCT05661851","Clinical Evaluation of a Multidose Preservative-free Lubricating Eye Drops Contained in Novelia® Eye Dropper in Non-Contact Lens Wearing Patients",[40],"2023-04-27","2023-02-23",121,[74],"Dry Eye",[76,77],"Investigational Lubricating Eye Drop in a Novelia® bottle","Blink® Tears eye Drops",{"trials":79,"activeCount":10},[],{"trials":81,"activeCount":10},[],{"trials":83,"activeCount":10},[],{"intervention":85,"totalTrials":8,"cells":86},"Blink® Tears eye drops in a multidose bottle",{"EARLY_PHASE1":87,"PHASE1":89,"PHASE2":91,"PHASE3":103,"PHASE4":105,"NA":107},{"trials":88,"activeCount":10},[],{"trials":90,"activeCount":10},[],{"trials":92,"activeCount":10},[93],{"nctId":94,"briefTitle":95,"status":56,"phases":96,"primaryCompletion":97,"completion":97,"start":98,"enrollment":99,"conditions":100,"interventions":101},"NCT05814367","Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops",[40],"2023-05-06","2023-04-06",46,[14],[85,102],"Preservative-free investigational lubricating eye drops in a Novelia® eyedropper",{"trials":104,"activeCount":10},[],{"trials":106,"activeCount":10},[],{"trials":108,"activeCount":10},[],{"intervention":102,"totalTrials":8,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":121,"PHASE4":123,"NA":125},{"trials":112,"activeCount":10},[],{"trials":114,"activeCount":10},[],{"trials":116,"activeCount":10},[117],{"nctId":94,"briefTitle":95,"status":56,"phases":118,"primaryCompletion":97,"completion":97,"start":98,"enrollment":99,"conditions":119,"interventions":120},[40],[14],[85,102],{"trials":122,"activeCount":10},[],{"trials":124,"activeCount":10},[],{"trials":126,"activeCount":10},[],{"intervention":128,"totalTrials":8,"cells":129},"etafilcon A with ketotifen",{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":145,"PHASE4":147,"NA":149},{"trials":131,"activeCount":10},[],{"trials":133,"activeCount":10},[],{"trials":135,"activeCount":10},[136],{"nctId":137,"briefTitle":138,"status":56,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":144},"NCT03388138","Clinical Evaluation of Etafilcon A With Ketotifen",[40],"2018-02-09","2017-12-06",143,[14],[128],{"trials":146,"activeCount":10},[],{"trials":148,"activeCount":10},[],{"trials":150,"activeCount":10},[],{"intervention":76,"totalTrials":8,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":163,"PHASE4":165,"NA":167},{"trials":154,"activeCount":10},[],{"trials":156,"activeCount":10},[],{"trials":158,"activeCount":10},[159],{"nctId":67,"briefTitle":68,"status":56,"phases":160,"primaryCompletion":70,"completion":70,"start":71,"enrollment":72,"conditions":161,"interventions":162},[40],[74],[76,77],{"trials":164,"activeCount":10},[],{"trials":166,"activeCount":10},[],{"trials":168,"activeCount":10},[],{"intervention":63,"totalTrials":8,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":185},{"trials":172,"activeCount":10},[],{"trials":174,"activeCount":10},[175],{"nctId":54,"briefTitle":55,"status":56,"phases":176,"primaryCompletion":58,"completion":58,"start":59,"enrollment":60,"conditions":177,"interventions":178},[39],[14],[46,63],{"trials":180,"activeCount":10},[],{"trials":182,"activeCount":10},[],{"trials":184,"activeCount":10},[],{"trials":186,"activeCount":10},[]]